PARP Goes Transcription
نویسندگان
چکیده
منابع مشابه
PARP Goes Transcription
PARP-1, an enzyme that catalyzes the attachment of ADP ribose units to target proteins, plays at least two important roles in transcription regulation. First, PARP-1 modifies histones and creates an anionic poly(ADPribose) matrix that binds histones, thereby promoting the decondensation of higher-order chromatin structures. Second, PARP-1 acts as a component of enhancer/promoter regulatory comp...
متن کاملTranscription goes digital.
Transcription is a complex process that integrates the state of the cell and its environment to generate adequate responses for cell fitness and survival. Recent microscopy experiments have been able to monitor transcription from single genes in individual cells. These observations have revealed two striking features: transcriptional activity can vary markedly from one cell to another, and is s...
متن کاملAs iron goes, so goes disease?
The brain iron overload disorders, collectively known as neurodegeneration with brain iron accumulation (NBIA), would seem to be tantalizing targets for chelation therapy. Efforts to lower brain iron in these disorders date back to the 1960s with deferoxamine mesylate, but systemic iron depletion limited its use. With the advent of chelators better able to specifically relieve central nervous s...
متن کاملPARP inhibitors
Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular ac...
متن کاملPARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCAdeficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF01367338, and MK-4827. Phase II studies of single-agent olaparib demonstrate ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell
سال: 2003
ISSN: 0092-8674
DOI: 10.1016/s0092-8674(03)00433-1